NO2789793T3 - - Google Patents
Info
- Publication number
- NO2789793T3 NO2789793T3 NO14172620A NO14172620A NO2789793T3 NO 2789793 T3 NO2789793 T3 NO 2789793T3 NO 14172620 A NO14172620 A NO 14172620A NO 14172620 A NO14172620 A NO 14172620A NO 2789793 T3 NO2789793 T3 NO 2789793T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261717743P | 2012-10-24 | 2012-10-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2789793T3 true NO2789793T3 (US07794700-20100914-C00152.png) | 2018-01-27 |
Family
ID=49488609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO14172620A NO2789793T3 (US07794700-20100914-C00152.png) | 2012-10-24 | 2012-04-24 |
Country Status (20)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014233385C1 (en) | 2013-03-15 | 2019-09-19 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
| WO2014194030A2 (en) * | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| EP3038624A1 (en) | 2013-08-26 | 2016-07-06 | Regeneron Pharmaceuticals, Inc. | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses |
| US10406198B2 (en) * | 2014-05-23 | 2019-09-10 | Novartis Ag | Methods for making conjugates from disulfide-containing proteins |
| US9951141B2 (en) | 2014-06-02 | 2018-04-24 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates, their preparation and their therapeutic use |
| GB2531715A (en) * | 2014-10-24 | 2016-05-04 | Polytherics Ltd | Novel drug conjugates |
| CN106794259B (zh) | 2014-10-14 | 2021-07-16 | 宝力泰锐克斯有限公司 | 采用包含含有peg部分的离去基团的试剂缀合肽或蛋白质的方法 |
| EP3220956B1 (en) * | 2014-10-24 | 2023-08-09 | Abzena (UK) Limited | Conjugates and conjugating reagents |
| CN113350518A (zh) | 2015-07-12 | 2021-09-07 | 杭州多禧生物科技有限公司 | 与细胞结合分子的共轭偶联的桥连接体 |
| US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
| WO2017025458A1 (en) * | 2015-08-07 | 2017-02-16 | Gamamabs Pharma | Antibodies, antibody drug conjugates and methods of use |
| MY198605A (en) | 2016-01-25 | 2023-09-08 | Regeneron Pharma | Maytansinoid derivatives conjugates thereof, and methods of use |
| WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
| JP7038663B2 (ja) | 2016-04-14 | 2022-03-18 | ポリセリックス・リミテッド | 環中に少なくとも２個の（－ｃｈ２－ｃｈ２－０－）単位を含むリンカーを含むコンジュゲート及びコンジュゲート試薬 |
| GB201608936D0 (en) | 2016-05-20 | 2016-07-06 | Polytherics Ltd | Novel conjugates and novel conjugating reagents |
| WO2017212250A1 (en) | 2016-06-06 | 2017-12-14 | Polytherics Limited | Antibodies, uses thereof and conjugates thereof |
| GB201615725D0 (en) * | 2016-09-15 | 2016-11-02 | Polytherics Ltd | Novel cytotoxic agents and conjugates thereof |
| CN116143678A (zh) | 2016-11-14 | 2023-05-23 | 杭州多禧生物科技有限公司 | 偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用 |
| US10864279B2 (en) | 2016-12-16 | 2020-12-15 | Industrial Technology Research Institute | Linker-drug and antibody-drug conjugate (ADC) employing the same |
| WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
| CA3145050A1 (en) | 2019-06-29 | 2021-01-07 | Robert Zhao | Conjugates of tubulysin derivatives and cell binding molecules and methods of making |
| US11918649B2 (en) | 2019-09-18 | 2024-03-05 | Molecular Templates, Inc. | PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds |
| EP4208259A2 (en) | 2020-09-04 | 2023-07-12 | NovaRock Biotherapeutics, Ltd. | Nectin-4 antibodies and uses thereof |
| US20220306700A1 (en) | 2021-03-17 | 2022-09-29 | Molecular Templates, Inc. | Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens |
| CN117147824A (zh) * | 2022-05-29 | 2023-12-01 | 菲鹏生物股份有限公司 | 一种抗体缀合物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| CN1938046B (zh) * | 2003-11-06 | 2014-03-19 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| AU2006294554B2 (en) * | 2005-09-26 | 2013-03-21 | E. R. Squibb & Sons, L.L.C. | Antibody-drug conjugates and methods of use |
| SI2211904T1 (sl) * | 2007-10-19 | 2016-12-30 | Seattle Genetics, Inc. | CD19 vezavna sredstva in njihove uporabe |
| JP2011523628A (ja) * | 2008-04-30 | 2011-08-18 | イミュノジェン・インコーポレーテッド | 有効なコンジュゲートおよび親水性リンカー |
| US9005598B2 (en) | 2009-03-04 | 2015-04-14 | Polytherics Limited | Conjugated proteins and peptides |
| TW201117814A (en) | 2009-10-02 | 2011-06-01 | Sanofi Aventis | New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody |
| EP2861261A2 (en) * | 2012-06-19 | 2015-04-22 | Polytherics Limited | Process for preparation of antibody conjugates and antibody conjugates |
-
2012
- 2012-04-24 NO NO14172620A patent/NO2789793T3/no unknown
-
2013
- 2013-10-11 JP JP2015538561A patent/JP6328649B2/ja active Active
- 2013-10-11 RU RU2015119557A patent/RU2015119557A/ru not_active Application Discontinuation
- 2013-10-11 BR BR112015008311A patent/BR112015008311A2/pt not_active Application Discontinuation
- 2013-10-11 IN IN2577DEN2015 patent/IN2015DN02577A/en unknown
- 2013-10-11 WO PCT/GB2013/052662 patent/WO2014064424A1/en active Application Filing
- 2013-10-11 AU AU2013336410A patent/AU2013336410B2/en active Active
- 2013-10-11 ES ES13783360.4T patent/ES2652513T3/es active Active
- 2013-10-11 HU HUE13783360A patent/HUE037604T2/hu unknown
- 2013-10-11 MX MX2015005124A patent/MX2015005124A/es unknown
- 2013-10-11 SG SG11201501955VA patent/SG11201501955VA/en unknown
- 2013-10-11 KR KR1020157009803A patent/KR20150085808A/ko not_active Application Discontinuation
- 2013-10-11 DK DK13783360.4T patent/DK2911696T3/en active
- 2013-10-11 CA CA2884359A patent/CA2884359A1/en not_active Abandoned
- 2013-10-11 CN CN201380055945.7A patent/CN104755106B/zh active Active
- 2013-10-11 US US14/437,571 patent/US20150283259A1/en not_active Abandoned
- 2013-10-11 EP EP13783360.4A patent/EP2911696B1/en active Active
-
2015
- 2015-03-11 IL IL237673A patent/IL237673A0/en unknown
- 2015-03-23 ZA ZA2015/01996A patent/ZA201501996B/en unknown
- 2015-09-11 HK HK15108931.8A patent/HK1208186A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP6328649B2 (ja) | 2018-05-23 |
| AU2013336410A1 (en) | 2015-04-09 |
| AU2013336410B2 (en) | 2017-08-03 |
| HK1208186A1 (en) | 2016-02-26 |
| ES2652513T3 (es) | 2018-02-02 |
| KR20150085808A (ko) | 2015-07-24 |
| HUE037604T2 (hu) | 2018-09-28 |
| ZA201501996B (en) | 2016-01-27 |
| IL237673A0 (en) | 2015-04-30 |
| WO2014064424A1 (en) | 2014-05-01 |
| CN104755106A (zh) | 2015-07-01 |
| MX2015005124A (es) | 2015-10-29 |
| RU2015119557A (ru) | 2016-12-20 |
| BR112015008311A2 (pt) | 2017-07-04 |
| EP2911696A1 (en) | 2015-09-02 |
| CA2884359A1 (en) | 2014-05-01 |
| DK2911696T3 (en) | 2018-01-08 |
| US20150283259A1 (en) | 2015-10-08 |
| EP2911696B1 (en) | 2017-09-20 |
| JP2015536329A (ja) | 2015-12-21 |
| IN2015DN02577A (US07794700-20100914-C00152.png) | 2015-09-11 |
| CN104755106B (zh) | 2018-03-13 |
| SG11201501955VA (en) | 2015-04-29 |
